Skip to Content

Tafenoquine use while Breastfeeding

Drugs containing Tafenoquine: Krintafel, Arakoda

Medically reviewed by Drugs.com. Last updated on Feb 22, 2021.

Tafenoquine Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. If tafenoquine is needed by the mother, testing the mother and infant for G6PD deficiency is required before the drug is given. Because the half-life of tafenoquine averages 15 days, the manufacturer recommends that breastfeeding should not breastfeed for 3 months after the dose if the infant is G6PD deficient.

Drug Levels

Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Primaquine

Substance Identification

Substance Name

Tafenoquine

CAS Registry Number

106635-80-7

Drug Class

  • Breast Feeding
  • Lactation
  • Anti-Infective Agents
  • Antiparasitic Agents
  • Antimalarials
  • Antiprotozoal Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.